RBPJL and esophageal squamous cell carcinoma: Mechanically, the p.P476S mutation of RBPJL in liver metastatic lesions markedly inhibited the NF‐κB pathway activated by RBPJL, thus dampening IL‐16 production in ESCC cell lines, leading to reduced chemotaxis and proliferation of T cell and Th2 to Th1 differentiation (Figure 7).